IAXO-102 is a small molecule TLR4 antagonist that suppresses downstream signaling, including MAPK and NF-kappaB activation, to reduce proinflammatory protein expression. It has demonstrated efficacy in preclinical models, such as inhibiting the development of abdominal aortic aneurysms in vivo.
